

**Editor**

Josef S Smolen

**Associate Editors**

Francis Berenbaum

Dimitrios Boumpas

Gerd Burmester

Mary Crow

Iain McInnes

Thomas Pap

David Pisetsky

Desirée van der Heijde

Kazuhiro Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases

BMJ Publishing Group Ltd

BMA House

Tavistock Square

London WC1H 9JR, UK

T: +44 (0)20 7383 6250

F: +44 (0)20 7383 6668

E: [ard@bmj.com](mailto:ard@bmj.com)

Twitter: @ARD\_BMJ

ISSN: 0003-4967 (print)

ISSN: 1468-2060 (online)

**Impact Factor:** 12.811

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2018 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431 POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

**Editorial**

- 473** Adalimumab concentration-based tapering strategy: as good as the recommended dosage  
*D Mulleman, A Balsa*

**Recommendation**

- 476** 2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis  
*H Radner, K Chatzidionysiou, E Nikephorou, L Gossec, K L Hyrich, C Zabalán, Y van Eijck-Hustings, P R Williamson, A Balanescu, G R Burmester, L Carmona, M Dougados, A Finckh, G Haugeberg, M L Heiland, S Oliver, D Porter, K Raza, P Ryan, M J Santos, A van der Helm-van Mil, P van Riel, G von Krause, J Zavadá, W G Dixon, J Asklíng*

**Viewpoint**

- 480** Implementation of the EULAR cardiovascular risk management guideline in patients with rheumatoid arthritis: results of a successful collaboration between primary and secondary care  
*J M Weijers, S A A Rongen-van Dartel, D M G M F Hoevenaars, M Rubens, M E J L Hulscher, P L C M van Riel*

**Clinical and epidemiological research**

- 484** Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial  
*M J J Ami, C L M Kriekkaert, M T Nurmohamed, R F van Vollenhoven, T Rispen, M Boers, G J Wolbink*
- 488** Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate  
*H Matsuno, M Tomomitsu, A Hagino, S Shin, J Lee, Y W Song*
- 495** Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial  
*R F van Vollenhoven, E C Keystone, V Strand, C Pacheco-Tena, J Vencovský, F Behrens, A Racewicz, D Zipp, F Rharbaoui, R Wolter, L Knierim, R Schmeidl, X Zhou, S Aigner, B Dälken, A Wartenberg-Demand, on behalf of the TREAT2b study team*
- 500** Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes  
*A Bérard, J-P Zhao, I Shui, S Colilla*

- 510** Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study  
*L Dreyer, R L Cordtz, I M J Hansen, L E Kristensen, M L Heiland, L Mellemejaer*
- 515** Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis  
*S Henaux, A Ruyssen-Witrand, A Cantagrel, T Barnetche, B Fautrel, N Filippi, C Lukas, B Rafféimer, M Rossini, Y Degboé, A Constantin*
- 523** Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation  
*S Glatt, D Baeten, T Baker, M Griffiths, L Ionescu, A D G Lawson, A Maroof, R Oliver, S Popa, F Strimenopoulou, P Vajjah, M I L Watling, N Yeremenko, P Miossec, S Shaw*
- 533** Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study  
*A Moltó, A Etcheto, L Gossec, N Boudersa, P Claudepierre, N Roux, L Lemeunier, A Martin, L Sparsa, P Coquerelle, M Soubrier, S Perrot, M Dougados*
- 541** Risk of cardiac rhythm disturbances and aortic regurgitation in different spondyloarthritis subtypes in comparison with general population: a register-based study from Sweden  
*K Bengtsson, H Forsblad-d'Elia, E Lie, E Klingberg, M Dehlin, S Exarchou, U Lindström, J Asklíng, L T H Jacobsson*

**MORE CONTENTS ►**

EDITOR'S CHOICE



OPEN ACCESS

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals Open Access scheme.

See <http://authors.bmj.com/open-access/>

Member since 2008  
JMS0004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

- 549** Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies  
*M Y Kim, M M Guerra, E Kaplowitz, C A Laskin, M Petri, D W Branch, M D Lockshin, L R Sammaritano, J T Merrill, T F Porter, A Sawitzke, A M Lynch, J P Buyon, J E Salmon*
- 556** Scoring hypoechogenic areas in one parotid and one submandibular gland increases feasibility of ultrasound in primary Sjögren's syndrome  
*E Mossel, S Arends, J F van Nimwegen, K Delli, A J Stel, F G M Kroese, F K L Spijkervet, A Vissink, H Bootsma, on behalf of the EULAR US-pSS study group*
- 563** Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study  
*A L Herrick, S Peytrignet, M Lunt, X Pan, R Hesselstrand, L Mouthon, A J Silman, G Dinsdale, E Brown, L Czirják, J H W Distler, O Distler, K Fligelstone, W J Gregory, R Ochiel, M C Vonk, C Ancaşa, V H Ong, D Farge, M Hudson, M Matucci-Cerinic, A Balbir-Gurman, Ø Midtvedt, P Johanputra, A C Jordan, W Stevens, P Moinzadeh, F C Hall, C Agard, M E Anderson, E Diot, R Madhok, M Akil, M H Buch, L Chung, N S Damjanov, H Gunawardena, P Lanyon, Y Ahmad, K Chakravarty, S Jacobsen, A J MacGregor, N McHugh, U Müller-Ladner, G Riemekasten, M Becker, J Roddy, P E Carreira, A L Fauchais, E Hachulla, J Hamilton, M Jnanç, J S McLaren, J M van Laar, S Pathare, S M Proudman, A Rudin, J Sahhar, B Coppere, C Serratrice, T Sheeran, D J Veale, C Grange, G-S Trad, C P Denton*
- 571** Mitochondrial genetic variation and gout in Māori and Pacific people living in Aotearoa New Zealand  
*A L Gosling, J Boockock, N Dalbeth, J Harré Hindmarsh, L K Stamp, E A Stahl, H K Choi, E A Matisoo-Smith, T R Merriman*
- 596** Changes in macrophage transcriptome associate with systemic sclerosis and mediate GSDMA contribution to disease risk  
*A Moreno-Moral, M Bagnati, S Koturan, J-H Ko, C Fonseca, N Harmston, L Game, J Martin, V Ong, D J Abraham, C P Denton, J Behmoaras, E Petretto*
- 602** Splicing variant of *WDFY4* augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis  
*Y Kochi, Y Kamatani, Y Kondo, A Suzuki, E Kawakami, R Hiwa, Y Momozawa, M Fujimoto, M Jinnin, Y Tanaka, T Kanda, R G Cooper, H Chinoy, S Rothwell, J A Lamb, J Vencovský, H Mann, K Ohmura, K Myouzen, K Ishigaki, R Nakashima, Y Hosono, H Tsuboi, H Kawasumi, Y Iwasaki, H Kajiyama, T Horita, M Ogawa-Momohara, A Takamura, S Tsumoda, J Shimizu, K Fujio, H Amano, A Mimori, A Kawakami, H Umehara, T Takeuchi, H Sano, Y Muro, T Aisumi, T Mimura, Y Kawaguchi, T Mimori, A Takahashi, M Kubo, H Kohsaka, T Sumida, K Yamamoto*
- 612** Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors  
*A Giannelou, H Wang, Q Zhou, Y H Park, M S Abu-Asab, K Ylaya, D L Stone, A Sediva, R Sleiman, L Sramkova, D Bhatla, E Serti, W L Tsai, D Yang, K Bishop, B Carrington, W Pei, N Deutch, S Brooks, J H Edwan, S Joshi, S Prader, D Kaiser, W C Owen, A A Sonbul, Y Zhang, J E Niemela, S M Burgess, M Boehm, B Rehermann, J J Chae, M M Quezado, A K Ombrello, R H Buckley, A A Grom, E F Remmers, J M Pachlopnik, H C Su, G Gutierrez-Cruz, S M Hewitt, R Sood, K Risma, K R Calvo, S D Rosenzweig, M Gadina, M Hafner, H-W Sun, D L Kastner, I Aksentijevich*
- 620** A novel variant in *GLIS3* is associated with osteoarthritis  
*E Casalone, I Tachmazidou, E Zengini, K Hatzikotoulas, S Hackinger, D Suveges, J Steinberg, N W Rayner, arcOGEN Consortium, J M Wilkinson, K Panoutsopoulou, E Zeggini*

## Basic and translational research

- 579** Visualising the interaction of CD4 T cells and DCs in the evolution of inflammatory arthritis  
*C T Prendergast, A Patakas, S Al-Khabouri, C L McIntyre, I B McInnes, J M Brewer, P Garside, R A Benson*
- 589** Cross-phenotype analysis of Immunochip data identifies *KDM4C* as a relevant *locus* for the development of systemic vasculitis  
*L Ortiz-Fernández, F D Carmona, R López-Mejías, M F González-Escribano, P A Lyons, A W Morgan, A H Sawalha, K G C Smith, M A González-Gay, J Martín, Spanish GCA Study Group, UK GCA Consortium, Turkish Takayasu Study Group, Vasculitis Clinical Research Consortium, IgAV Study Group, AAV Study group*
- 625** Application of the 2015/2016 EULAR recommendations for cardiovascular risk in daily practice: data from an observational study  
*C I Daien, A Tubery, G du Cailar, T Mura, F Roubille, J Morel, J Bousquet, P Fesler, B Combe*
- 626** Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis  
*C Beyer, D Huscher, A Ramming, C Bergmann, J Avouac, S Guiducci, F Meier, S Vettori, E Siegert, V K Jaeger, B Maurer, G Riemekasten, U Walker, U Müller-Ladner, G Valentini, M Matucci-Cerinic, Y Allnore, O Distler, G Schett, J H W Distler*

## Letters

- 629** Advanced imaging assessment of gout: comparison of dual-energy CT and MRI with anatomical pathology

*A Chhana, A Doyle, A Sevaio, S Amirapu, P Riordan, M Dray, S McGlashan, J Cornish, N Dalbeth*

---

### Correction

- 623** Correction: 2016 American college of rheumatology/European league against rheumatism criteria for minimal moderate, and major clinical response in juvenile dermatomyositis

---

### Electronic pages

- e18** Important but incomplete data analysis?  
*P Sewerin, A Hoyer, M Schneider, B Ostendorf, R Brinks*

- e19** Impact of age and sex on the incidence and prevalence of psoriatic arthritis

*A Egeberg, L E Kristensen*

- e20** EULAR gout treatment guidelines by Richette *et al.*: uric acid and neurocognition

*J A Singh, N L Edwards*

- e21** SUA levels should not be maintained <3 mg/dL for several years. Response to 'EULAR gout treatment guidelines by Richette *et al.*: uric acid and neurocognition by Singh *et al.*'

*P Richette, M Doherty, E Pascual, T Bardin*

- e22** Thank you to our reviewers 2017